IRVINE, Calif., October 29, 2021 / PRNewswire / – AIVITA Biomedical, Inc., a biotechnology company specializing in innovative stem cell applications, today announced the publication of the peer-reviewed manuscript, “Co-grafts of Human Stem Cell Derived Retina Organoids and Retinal Pigment Epithelium for Retinal Reconstruction in Immunodeficient Retinal Degenerates Royal College of Surgeons Rats “, in the newspaper Frontiers in neuroscience. The to study, led by researchers from AIVITA Biomedical and the Stem Cell Research Center of University of California, Irvine, used retinal organoids and polarized retinal pigment epithelium sheets generated from human stem cells developed by AIVITA to test their viability as a “total retinal patch” for vision loss.
In this study, in vivo transplantation experiments were carried out in Royal College of Surgeons rats in advanced stages of retinal degeneration. Structural reconstruction of the severely damaged retina has been observed in transplanted animals based on histological evaluations and optical coherence tomography imaging. Assessments of visual function were performed by behavioral optokinetic testing and superior electrophysiology of the collicus. Long-term survival of the cograft in the rat subretinal space and improvement in visual function were observed. Immunohistochemistry showed that the co-grafts grew, generated new photoreceptors, and developed neural processes that were integrated into the host’s retina.
“These results demonstrate the potential of this approach in the treatment of common retinal degenerative conditions such as end-stage age-related macular degeneration, retinitis pigmentosa and retinal damage due to injury,” said Dr. Hans S. Keirstead, Chairman and CEO of AIVITA Biomedical.
About AIVITA Biomedical
Founded in 2016 by pioneers in the cell therapy industry, AIVITA Biomedical, Inc. uses its expertise in stem cell growth and high purity directed differentiation to enable safe, efficient and economical manufacturing systems that support its therapeutic pipeline. Our cancer immunotherapy targets the seed of all cancers, the tumor-initiating stem cells, with a unique pan-antigenic approach that targets all of the patient’s cancer-specific neoantigens. Our patient-specific cancer treatments have shown tremendous promise in eradicating tumors without harmful side effects in clinical studies of melanoma and glioblastoma.
Caution Regarding Forward-Looking Statements
This communication contains statements that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, if applicable. Forward-looking statements include, without limitation, statements regarding our plans, beliefs, expectations and assumptions, as well as other statements that are not necessarily historical facts. You are cautioned that these forward-looking statements are only predictions and involve risks and uncertainties. In addition, any forward-looking statement speaks only as of the date on which it is made, and we do not intend to update or revise any forward-looking statements. This communication also contains market data relating to our business and our industry, including projections based on a number of assumptions that we consider reasonable and the most significant compared to projections at the date of this communication. If any of our assumptions prove to be incorrect, our actual results may differ materially from our projections based on those assumptions. This communication is neither an offer to sell nor a solicitation of an offer to buy the securities described herein.
SOURCE AIVITA Biomedical, Inc.